Karyopharm shares slide on earnings miss, cash runway concerns
Biotech misses Q4 revenue estimates, reveals liquidity will only sustain operations through mid-2026 amid heavy debt load
Karyopharm Therapeutics shares fell sharply Thursday after the cancer drug developer reported quarterly results that missed analyst expectations and revealed a shrinking cash pile that will only fund operations into the second quarter of 2026.
The Newton, Massachusetts-based biotechnology company reported preliminary fourth-quarter revenue of approximately $33 million, missing Wall Street expectations of $42.4 million by 19.6%. The earnings shortfall extended to the bottom line, with the company posting a loss per share of $5.71, significantly worse than the projected loss of $3.25.
Most concerning for investors was the company's deteriorating financial position. Karyopharm ended 2025 with $64 million in cash and cash equivalents, down 41% from the previous year. At current burn rates, the company stated its liquidity will only sustain operations through the second quarter of 2026, raising questions about its ability to fund ongoing clinical trials and commercialization efforts without additional capital.
The company's debt burden adds further pressure to the balance sheet. Karyopharm carries $226.9 million in debt, a substantial load for a company with a market capitalization of roughly $121 million. This leverage limits financial flexibility and could force the company into dilutive financing or unfavorable debt restructuring as its cash dwindles.
For 2026, Karyopharm issued guidance essentially flat with 2025 performance, projecting revenue of $130 million to $150 million compared to full-year 2025 revenue of approximately $146 million. The lack of growth disappointed analysts who had been expecting acceleration as the company's flagship XPOVIO therapy gained broader market acceptance.
XPOVIO, Karyopharm's primary commercial product, generated U.S. net product revenue of approximately $32 million in the fourth quarter and $115 million for the full year. The therapy, which uses the company's proprietary SINE technology to treat certain blood cancers, has secured multiple regulatory approvals but faces increasing competition in the oncology landscape.
Prior to the earnings announcement, analysts maintained a generally positive outlook on Karyopharm, with consensus ratings ranging from "Moderate Buy" to "Buy" and average 12-month price targets between $14.83 and $22.17. Those targets may now be at risk as investors reassess the company's path to profitability and funding requirements.
The company's shares had already declined 3.3% on February 5 when it announced the earnings release date, suggesting anticipation of weak results. The stock is currently trading at $7.37, well below its 52-week high of $10.38 and only modestly above its 52-week low of $3.51.
Karyopharm's profitability metrics remain deeply negative, with trailing twelve-month earnings per share of -$15.40 and a profit margin of -87.4%. The company's book value stands at -$30.94 per share, reflecting accumulated losses that have eroded shareholder equity.
Six analysts currently cover Karyopharm, with two rating it a Strong Buy, three recommending Buy, and one advising Hold. That bullish consensus may face reassessment in the coming days as analysts digest the implications of the company's constrained cash position and limited growth guidance.
Biotechnology investors typically tolerate high burn rates and deep losses when companies demonstrate clear paths to regulatory milestones and commercial success. However, Karyopharm's combination of missed earnings expectations, flat revenue guidance, and dwindling liquidity runway creates a precarious outlook that could force management to pursue capital raises at unfavorable terms or pause development programs to preserve cash.